RETRACTED ARTICLE: Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Background Chronic intestinal inflammation alters host physiology and could lead to colorectal cancer (CRC). We have previously reported beneficial effects of the probiotic strain of Lactobacillus casei BL23 in different murine models of intestinal inflammation. In addition, there is an emerging interest on the potential beneficial effects of probiotics to treat CRC. We thus explored whether L. casei BL23 displays protective effects on CRC.Methods Mice were subcutaneously injected with 1,2-dimethylhydrazine (DMH) weekly during 10 weeks and orally administered with L. casei BL23 in the drinking water until the 10th week. Multiple plaque lesions in the large intestine were observed macroscopically and counted and intestinal tissues were also histologically analyzed. Finally, T-cell populations and cytokine production were evaluated after co-incubation of L. casei BL23 with spleen cells from non-treated mice to determine the immuno-modulatory effects of this bacterium.Results Our results show that oral treatment with this probiotic bacterium modulates host immune responses and significantly protect mice against DMH-induced CRC. This protection may be associated with the modulation of regulatory T-cells towards a Th17-biased immune response accompanied by the expression of regulatory cytokines (IL-6, IL-17, IL-10 and TGF-β), as demonstrated in L. casei BL23-treated splenocytes, but also with the colonic expression of IL-22 observed in vivo on L. casei BL23-treated mice; suggesting the induction of a fine-tune Th17-biased response.Conclusions Altogether our results reveal the high potential of L. casei BL23 to treat CRC and opens new frontiers for the study of immunomodulatory functions of probiotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been also reported in several studies that Lactobacilli may stimulate host’s immune cells such as NK cells or dendritic cells (DC) or TH1 response, which, in turn, leads to the elimination of cancerous or precancerous cells, although the exact bacterial bioproduct mediating such stimulatory effect still needs to be identified [45,46,47,48].”
From Gut Microbiota and Cancer: From Pathogenesis to Therapy (2019) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 1×
“method of Bradford [32].”
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050 · cited 1×
“Currently, some studies have demonstrated that both probiotic bacteria and gut microbiota [2] could be an alternative approach to prevent and treat a number of human diseases including cancer and CRC [3, 4].”
BackgroundGasson, M. J. (1983) · Journal of Bacteriology · doi:10.1128/jb.154.1.1-9.1983 · Cited by 1,322 · cited 7×
“Data are represented as individual tumors volumes from mice at the end of week 10 (median of the size is shown by bars), Student’s t test, *p\ 0.001 (A) (B) Microscopic damage score Mo nth 3 Mo nth 4 Mo nth 5 Mo nth 6 0 2 4 6 8 10 12 DMH L. lactis MG1363 L. casei BL23 M ic ro sc op ic s co re ** MPL Mo nth 3 Mo nth 4…”
MethodInfluentialTosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146 · cited 1×
“and an increase in Treg populations are most related to a beneficial effect in cancer (including CRC) [39–42].”
BackgroundLin, K. Y., Guarnieri, F., Staveley-O’Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., & Wu, T. ‐. (1996) · PubMed · Cited by 1,003
The microbiota regulates type 2 immunity through RORγt + T cells
Ohnmacht, C., Park, J.-H., Cording, S., Wing, J. B., Atarashi, K., Obata, Y., Gaboriau-Routhiau, V., Marques, R., Dulauroy, S., Fedoseeva, M., et al. (2015) · Science · doi:10.1126/science.aac4263 · Cited by 863
Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice
Madsen, K. L., Doyle, J. S., Jewell, L. D., Tavernini, M. M., & Fedorak, R. N. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70013-2 · Cited by 761 · cited 3×
“For example, it has been reported that administration of Lactobacillus reuteri prevented colitis in IL-10 KO mice by increasing the number of LAB in the GIT [7].”
Background
Cited by
Probiotic species in the modulation of gut microbiota: An overview
Azad, M. A. K., Sarker, M., Li, T., & Yin, J. (2018) · BioMed Research International · doi:10.1155/2018/9478630 · Cited by 803
“casei BL23 Female C57BL/6 mice CRC ↑Th17, Th 22, IL-10, and IL-22 ↓ Treg [19, 20]”
BackgroundAdhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health
Monteagudo-Mera, A., Rastall, R. A., Gibson, G. R., Charalampopoulos, D., & Chatzifragkou, A. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09978-7 · Cited by 743
“Conversely, probiotic bacteria could suppress pathogenic Th17 cells and induce steady-state Th17 cells (Lenoir et al. 2016).”
BackgroundGut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer
Fong, W., Li, Q., & Yu, J. (2020) · Oncogene · doi:10.1038/s41388-020-1341-1 · Cited by 613
“While downregulation of proinflammatory cytokines (MCP-1, TNF-α) and upregulation of IL-10 is observed in intestinal content, splenocyte analysis has demonstrated the decreased Treg level and increased Th17 population at the systemic level, thus triggering a Th17/Treg mixed-type immune response [31].”
BackgroundGut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Anticancer effects of the microbiome and its products
Zitvogel, L., Daillère, R., Roberti, M. P., Routy, B., & Kroemer, G. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.44 · Cited by 538
Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential
Saus, E., Iraola-Guzmán, S., Willis, J. R., Brunet-Vega, A., & Gabaldón, T. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.001 · Cited by 350
Probiotic Bacteria: A Promising Tool in Cancer Prevention and Therapy
Górska, A., Przystupski, D., Niemczura, M. J., & Kulbacka, J. (2019) · Current Microbiology · doi:10.1007/s00284-019-01679-8 · Cited by 344
The mutual interplay of gut microbiota, diet and human disease
Illiano, P., Brambilla, R., & Parolini, C. (2020) · The FEBS Journal · doi:10.1111/febs.15217 · Cited by 322
The Role of Probiotics in Cancer Prevention
Śliżewska, K., Markowiak-Kopeć, P., & Śliżewska, W. (2020) · Cancers · doi:10.3390/cancers13010020 · Cited by 282
Microbiome, inflammation and colorectal cancer
Chen, J., Pitmon, E., & Wang, K. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.006 · Cited by 265
Probiotic Strain Lactobacillus casei BL23 Prevents Colitis‐Associated Colorectal Cancer
Jacouton, E., Chain, F., Sokol, H., Langella, P., & Bermúdez-Humarán, L. G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01553 · Cited by 249
“We attributed this antitumoral effect to a modulation of the immune response and, in particular, to the modulation of regulatory T-cells toward a Th17-biased immune response associated with the expression of regulatory cytokines (IL-6, IL-17, IL-10, and TGF-β) (25).”
BackgroundInfluentialSelf-citationRadiotherapy and the gut microbiome: facts and fiction
Liu, J., Liu, C., & Yue, J. (2021) · Radiation Oncology · doi:10.1186/s13014-020-01735-9 · Cited by 183
Potential Mechanisms of Probiotics Action in the Prevention and Treatment of Colorectal Cancer
Molska, M., & Reguła, J. (2019) · Nutrients · doi:10.3390/nu11102453 · Cited by 178
Tweak to Treat: Reprograming Bacteria for Cancer Treatment
Sieow, B. F.-L., Wun, K. S., Yong, W. P., Hwang, I. Y., & Chang, M. W. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.11.004 · Cited by 158
Chang (2018) · doi:10.3389/fmicb.2018.00983 · Cited by 152
Rubio, A. P. D., Martínez, J. H., Martínez-Casillas, D. C., Leskow, F. C., Piuri, M., & Pérez, O. E. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01783 · Cited by 137
“Additionally, L. casei BL23 orally inoculated mice have shown a decrease of Listeria monocytogenes systemic dissemination (Archambaud et al., 2012) and a modulation of the host immune response protecting mice against induced colorectal cancer (Lenoir et al., 2016).”
BackgroundThe Role of Probiotics in Colorectal Cancer Management
Sivamaruthi, B. S., Kesika, P., & Chaiyasut, C. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/3535982 · Cited by 118
“casei BL23 (10 μl; 1× 10 8 CFU/μl) 3 days (on days 0, 14, 28) ↓ incidence of tumor ↓ multiple plaque lesions Regulates the Treg and )17 T cells Altered the expression of IL-6, IL-10, IL-17, and TGF-β [45]”
BackgroundInfluentialSun, J., Chen, F., & Wu, G. (2023) · The ISME Journal · doi:10.1038/s41396-023-01483-0 · Cited by 126
Yue, Y., Ye, K., Lü, J., Wang, X., Zhang, S., Liu, L., Yang, B., Nassar, K. S., Xu, X., Pang, X., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110159 · Cited by 123
Receptor-targeted engineered probiotics mitigate lethal Listeria infection
Drolia, R., Amalaradjou, M. A. R., Ryan, V., Tenguria, S., Liu, D., Bai, X., Xu, L., Singh, A. K., Cox, A. D., Bernal-Crespo, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20200-5 · Cited by 112
Large-scale microbiome data integration enables robust biomarker identification
Xiao, L., Zhang, F., & Zhao, F. (2022) · Nature Computational Science · doi:10.1038/s43588-022-00247-8 · Cited by 102
Chen, H., Zhang, F., Zhang, J., Zhang, X., Guo, Y., & Yao, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.588079 · Cited by 102
“With the developing of microbiome technology, the dysbiosis in CRC has been further found to involve in the decrease of some beneficial bacteria, such as Lactobacillus, Eubacterium rectale (20), and increase of pathogenic bacteria, such as Fusobacterium nucleatum, Escherichia coli (21).”
BackgroundThe impact of the intestinal microbiota in therapeutic responses against cancer
Goubet, A., Daillère, R., Routy, B., Derosa, L., Roberti, P. M., & Zitvogel, L. (2018) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2018.03.004 · Cited by 100
Probiotics-mediated suppression of cancer
So, S. S. Y., Wan, M. L. Y., & El-Nezami, H. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000342 · Cited by 88
Wang, Z., Hua, W., Li, C., Chang, H., Liu, R., Ni, Y., Sun, H., Li, Y., Wang, X., Hou, M., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02498 · Cited by 86
“Previous studies had introduced single or several bacteria complex strains to treat CAC (Lenoir et al., 2016; Mendes et al., 2018).”
BackgroundPerillo, F., Amoroso, C., Strati, F., Giuffrè, M. R., Díaz‐Basabe, A., Lattanzi, G., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155389 · Cited by 91
Implication of Obesity and Gut Microbiome Dysbiosis in the Etiology of Colorectal Cancer
Singh, S., Sharma, P., Sarma, D. K., Kumawat, M., Tiwari, R. R., Verma, V., Nagpal, R., & Kumar, M. (2023) · Cancers · doi:10.3390/cancers15061913 · Cited by 90
del Carmen, S., de LeBlanc, A. D. M., Levit, R., Azevedo, V., Langella, P., Bermúdez‐Humarán, L. G., & LeBlanc, J. G. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.11.017 · Cited by 84
Self-citationThe human gastrointestinal microbiota and prostate cancer development and treatment
Sha, S. T., Ni, L., Stefil, M., Dixon, M. R., & MOURAVIEV, V. B. (2020) · Korean journal of urology · doi:10.4111/icu.2020.61.s1.s43 · Cited by 83
“There has been increasing interest in the microbiome’s role in cancer development and progression, and studies show that distinct microbiota can both promote and inhibit tumor development [14-20].”
BackgroundProbiotics, mechanisms of action, and clinical perspectives for diarrhea management in children
do Carmo, M. S., Santos, C. I. D., Araújo, M. C., Girón, J. A., Fernandes, E. S., & Monteiro-Neto, V. (2018) · Food & Function · doi:10.1039/c8fo00376a · Cited by 75
Xiu, L., Zhang, H., Hu, Z., Liang, Y., Guo, S., Yang, M., Du, R., & Wang, X. (2018) · Food and Agricultural Immunology · doi:10.1080/09540105.2018.1513994 · Cited by 73
Optimization of Culturomics Strategy in Human Fecal Samples
Chang, Y., Hou, F., Pan, Z., Huang, Z., Han, N., Bin, L., Deng, H., Li, Z., Ding, L., Gao, H., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02891 · Cited by 77
Microbe-based therapies for colorectal cancer: Advantages and limitations
Saeed, M., Shoaib, A., Kandimalla, R., Javed, S., Almatroudi, A., Gupta, R. C., & Aqil, F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.018 · Cited by 74
Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics
Ding, C., Tang, W., Fan, X., & Wu, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170626 · Cited by 69
“have been successfully conducted for IM-based CRC therapies in animal models by using pro-/prebiotics.(33,34) Additionally, targeted gut microbiome might be an effective strategy for preventing the progression of inflammation-driven CRC under antibiotic treatment.”
Chandel, D., Sharma, M., Chawla, V., Sachdeva, N., & Shukla, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-51361-z · Cited by 67
Allemailem, K. S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s338272 · Cited by 67
“Wild-type probiotics have been used to study bladder cancer, cervical cancer, breast cancer, liver cancer, in addition to colorectal cancer.(24) These probiotics can be directly delivered at the TME to reduce non-specific pharmacological effects on normal tissues.”
Probiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
An Update on the Effects of Probiotics on Gastrointestinal Cancers
Davoodvandi, A., Fallahi, F., Tamtaji, O. R., Tajiknia, V., Banikazemi, Z., Fathizadeh, H., Abbasi‐Kolli, M., Aschner, M., Ghandali, M., Sahebkar, A., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.680400 · Cited by 61
The Human Microbiota and Prostate Cancer: Friend or Foe?
Massari, F., Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., López-Beltrán, A., Cheng, L., Battelli, N., et al. (2019) · Cancers · doi:10.3390/cancers11040459 · Cited by 62
Rong, J., Liu, S., Hu, C., & Liu, C. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14516 · Cited by 62
Protective Effect of Lactobacillus casei on DMH-Induced Colon Carcinogenesis in Mice
Irecta-Nájera, C. A., Huizar-López, M. D. R., Casas‐Solís, J., Castro-Félix, P., & Santerre, A. (2017) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-017-9253-2 · Cited by 53
Structural studies of the rhamnose-rich cell wall polysaccharide of Lactobacillus casei BL23
VINOGRADOV, E. V., Sadovskaya, I., Grard, T., & Chapot, M.-P. (2016) · Carbohydrate Research · doi:10.1016/j.carres.2016.10.002 · Cited by 51
Jacouton, E., Michel, M., Torres-Maravilla, E., Chain, F., Langella, P., & Bermúdez‐Humarán, L. G. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03281 · Cited by 55
Self-citationRole of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review
Han, S., Gao, J., Zhou, Q., Liu, S., Wen, C., & Xi, Y. (2018) · Cancer Management and Research · doi:10.2147/cmar.s153482 · Cited by 54
Microbial Interactions and Interventions in Colorectal Cancer
Raay, T. J. V., & Allen‐Vercoe, E. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0004-2016 · Cited by 51
Role of Inflammation in Pathophysiology of Colonic Disease: An Update
Nasef, N. A., & Mehta, S. Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134748 · Cited by 49
Xin, Y., Guo, T., Mu, Y., & Kong, J. (2017) · FEMS Microbiology Letters · doi:10.1093/femsle/fnx243 · Cited by 46
“Due to the virtue of generally regarded as safe status, certain L. casei strains have been suggested to possess potential therapeutic effects (Kato-Kataoka et al. 2016; Lenoir et al. 2016).”
BackgroundSouza, R. D. F. S., Rault, L., Seyffert, N., Azevedo, V., Loir, Y. L., & Even, S. (2018) · Beneficial Microbes · doi:10.3920/bm2018.0010 · Cited by 50
Potential Ability of Probiotics in the Prevention and Treatment of Colorectal Cancer
Zhao, J., Liao, Y., Wei, C., Ma, Y., Wang, F., Chen, Y., Zhao, B., Ji, H., Wang, D., & Tang, D. (2023) · Clinical Medicine Insights: Oncology · doi:10.1177/11795549231188225 · Cited by 35
Huang, S., Gaucher, F., Cauty, C., Jardin, J., Loir, Y. L., Jeantet, R., Chen, X. D., & Jan, G. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02548 · Cited by 45
Chen, Y., Ma, W., Zhao, J., Stanton, C., Ross, R. P., Zhang, H., Chen, W., & Yang, B. K. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c02824 · Cited by 44
Anti-tumoral Effects of Recombinant Lactococcus lactis Strain Secreting IL-17A Cytokine
Jacouton, E., Torres-Maravilla, E., Boucard, A.-S., Pouderous, N., Vilela, A. P. P., Naas, I., Chain, F., Azevedo, V., Langella, P., & Bermúdez‐Humarán, L. G. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03355 · Cited by 45
“, IL-6, IL-17, IL10, and TGF-β), in a murine model of CRC (Lenoir et al., 2016).”
BackgroundSelf-citationBacteriotherapy in gastrointestinal cancer
Soleimanpour, S., Hasanian, S. M., Avan, A., Yaghoubi, A., & Khazaei, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117754 · Cited by 47
Panebianco, C., Latiano, T. P., & Pazienza, V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00679 · Cited by 46
“In the first case, L. casei BL23 was found tomodulate host immunity, shifting toward a Th17-response (16), whereas in the second case inhibition of cell proliferation and promotion of apoptosis by the probiotic were demonstrated (17).”
BackgroundInfluentialMolecular crosstalk between polyphenols and gut microbiota in cancer prevention
Zeb, F., Naqeeb, H., Osaili, T. M. I., Faris, M. E., Ismail, L. C., Obaid, R. S., Naja, F., Radwan, H. M., Hasan, H. A., Hashim, M. S., et al. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.01.012 · Cited by 40
Modulation of Anti-Tumour Immune Responses by Probiotic Bacteria
Aindelis, G., & Chlichlia, K. (2020) · Vaccines · doi:10.3390/vaccines8020329 · Cited by 43
“[96] reported that, in C57BL/6 mice treated with DMH and Lactobacillus casei BL23, the secretion of cytokines was altered in response to probiotic administration and balanced Th17 responses emerged, culminating in the reduction of tumour incidence.”
BackgroundSharma, P., Kaur, S., Kaur, R., Kaur, M., & Kaur, S. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00948 · Cited by 38
“LAB probiotics are mostly shown to inhibit the growth of cancer cells indirectly through enhancing the adaptive immunity by inducing cytotoxic T cells (Lenoir et al., 2016), NK cells (Takagi et al.”
BackgroundChondrou, P., Karapetsas, A., Kiousi, D. E., Vasileiadis, S., Ypsilantis, P., Botaitis, S., Alexopoulos, A., Plessas, S., Bezirtzoglou, E., & Galanis, Α. (2020) · Microorganisms · doi:10.3390/microorganisms8050709 · Cited by 43
“Similarly, the probiotic strain Lactobacillus casei BL23 promoted a Th17-biased immune response, followed by the expression of proinflammatory cytokines (IL-6, IL-17, IL-10, and TGF-β), in a mouse model of intestinal inflammation [19].”
BackgroundKinany, K. E., Deoula, M. M. S., Hatime, Z., Boudouaya, H. A., Huybrechts, I., Asri, A. E., Benider, A., Ahallat, M., Afqir, S., Mellas, N., et al. (2019) · European Journal of Nutrition · doi:10.1007/s00394-019-01954-1 · Cited by 40
Kim, S.-J., Kang, C.-H., Kim, G., & Cho, H. (2022) · Microorganisms · doi:10.3390/microorganisms10030533 · Cited by 37
“casei was reported to protect mice against DMH-induced CRC, which partly agrees with our in vivo study results [29,30].”
ResultKoduru, L., Lakshmanan, M., Lee, Y. Q., Ho, P. L., Lim, P. Y., Ler, W. X., Ng, S. K., Kim, D., Park, D., Banu, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111735 · Cited by 37
Djaldetti, M., & Bessler, H. (2017) · FEMS Microbiology Letters · doi:10.1093/femsle/fnx014 · Cited by 33
“Mouse splenocytes treated with L. casei BL 23 showed increased generation of IL-6, IL-17, IL-10 and TGF-β (Lenoir et al. 2016).”
BackgroundResultInfluentialUpdate on Strategies of Probiotics for the Prevention and Treatment of Colorectal Cancer
Tang, G., & Zhang, L. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1865420 · Cited by 34
“found that Lactobacillus casei BL23 can reduce the occurrence of CRC by reducing the number of Th17 T-cells (42), which are a class of helper cells that secrete cyto-”
BackgroundImmunomodulatory Effect of Lactobacillus casei in a Murine Model of Colon Carcinogenesis
Casas‐Solís, J., Huizar-López, M. D. R., Irecta-Nájera, C. A., Pita‐López, M. L., & Santerre, A. (2019) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-019-09611-z · Cited by 32
The Microbiome and Its Implications in Cancer Immunotherapy
Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31
Preclinical Evidence of Probiotics in Colorectal Carcinogenesis: A Systematic Review
Brasiel, P. G. D. A., Luquetti, S. C. P. D., Pelúzio, M. D. C. G., Novaes, R. D., & Gonçalves, R. V. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06062-3 · Cited by 55
“05) Lactobacillus casei Reduction n = 6 n = 5 n = 10 Percentage of ACF [39] Number of damage score [45] Number of ACF [47] 45% (p < 0.”
BackgroundChanges to the gut microbiota in mice induced by infection with Toxoplasma gondii
Shao, D., Bai, X., Tong, M., Zhang, Y. Y., Liu, X. L., Zhou, Y. H., Li, C., Cai, W., Gao, X., Liu, M., et al. (2019) · Acta Tropica · doi:10.1016/j.actatropica.2019.105301 · Cited by 29
Gut Microbiota and Immune Responses
Dong, L., Xie, J., Wang, Y., & Zuo, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_10 · Cited by 31
The role of gut microbiota in the development of colorectal cancer: a review
Koyande, N. P., Gangopadhyay, M., Thatikonda, S., & Rengan, A. K. (2022) · International Journal of Colorectal Disease · doi:10.1007/s00384-022-04192-w · Cited by 30
Kim, S.-J., Lee, H. H., Choi, W., Kang, C.-H., Kim, G., & Cho, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179788 · Cited by 29
“A recent report that probiotic-derived molecules exhibit tumor growth inhibitory effects in a xenograft model partly agrees with our in vivo results [40,41].”
ResultNoninvasive PET tracking of post-transplant gut microbiota in living mice
Wang, Y., Zhang, C., Lai, J., Zhao, Y., Lu, D., Bao, R., Feng, X., Zhang, T., & Liu, Z. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04639-3 · Cited by 26
Increase in Akkermansiaceae in Gut Microbiota of Prostate Cancer-Bearing Mice
Huang, P.-Y., Yang, Y., Wang, C., Hsiao, P., Chiang, H., & Chen, T.-W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179626 · Cited by 27
Jaskulski, I. B., Uecker, J. N., Bordini, F. W., de Moura, F. A., Gonçalves, T., Chaves, N. G., Camargo, F. A. D. O., Grecco, F. B., Fiorentini, Â. M., da Silva, W. P., et al. (2019) · Process Biochemistry · doi:10.1016/j.procbio.2019.12.008 · Cited by 26
Mathipa-Mdakane, M. G., Thantsha, M. S., & Bhunia, A. K. (2019) · Microbial Biotechnology · doi:10.1111/1751-7915.13407 · Cited by 26
Intervention on gut microbiota may change the strategy for management of colorectal cancer
Taghinezhad‐S, S., Mohseni, A. H., & Fu, X. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15369 · Cited by 24
Cortes‐Perez, N. G., Lozano‐Ojalvo, D., Maiga, M. A., Hazebrouck, S., & Adel‐Patient, K. (2017) · Beneficial Microbes · doi:10.3920/bm2016.0174 · Cited by 23
“Additionally, oral treatment with the BL23 strain protects mice against 1,2-dimethylhydrazine (DMH)-induced colorectal cancer (Lenoir et al., 2016).”
BackgroundMethodSelf-citationJameel, M., & Kwok, H. F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.011 · Cited by 22
Chemopreventive role of probiotics against cancer: a comprehensive mechanistic review
Noor, S., Ali, S., Riaz, S., Sardar, I., Farooq, M. A., & Sajjad, A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08023-7 · Cited by 23
Current status of probiotics for prevention and management of gastrointestinal cancers
Khan, A. A., Nema, V., & Khan, Z. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1828858 · Cited by 20
Cruz, B. C. D. S., Moraes, L. F. D. S., Marcon, L., Dias, K. A., Murad, L. B., Sarandy, M. M., da Conceição, L. L., Gonçalves, R. V., Ferreira, C. L. D. L. F., & Pelúzio, M. D. C. G. (2021) · Journal of Food Science · doi:10.1111/1750-3841.15690 · Cited by 20
Lipopeptide(s) associated with human microbiome as potent cancer drug
Chauhan, V., & Kanwar, S. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.012 · Cited by 19
Rahimi, A. M., Nabavizadeh, F., Ashabi, G., Halimi, S., Rahimpour, M., Vahedian, J., & Panahi, M. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1832237 · Cited by 19
“Previous studies also have reported that lactobacilli display protective effects against colorectal cancer by reinforcing and modulating the host immune response (24).”
ResultImportance of Probiotics in Cancer Prevention and Treatment
Sharma, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816328-3.00004-0 · Cited by 18
Secondary Metabolites From Probiotic Metabolism
Chávarri, M., Diez-Gutiérrez, L., Marañón, I., & Barrón, L. J. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822909-5.00017-4 · Cited by 21
Bugs, drugs, and cancer: can the microbiome be a potential therapeutic target for cancer management?
Chen, B., Du, G., Guo, J., & Zhang, Y. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.009 · Cited by 18
A Single-Plasmid Genome Editing System for Metabolic Engineering of Lactobacillus casei
Xin, Y., Guo, T., Mu, Y., & Kong, J. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03024 · Cited by 16
Relationship Between Intestinal Microorganisms and T Lymphocytes In Colorectal Cancer
Han, S., Xi, Y., Quan, Q., Pan, Y., Da, M., & Zhou, Q. (2019) · Future Oncology · doi:10.2217/fon-2018-0595 · Cited by 16
Arteaga-Henríquez, G., Ramos-Sayalero, C., Ibañez-Jiménez, P., Rosales-Ortiz, S. K., Kilencz, T., Schiweck, C., Schnorr, I., Siegl, A., Vásquez, A. A., Bitter, I., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.06.012 · Cited by 19
“…animal and human studies has repeatedly suggested that several bacterial strains, such as Lactobacillus casei , Lactobacillus plantarum may exert their action by acting as modulators of the IL-23/IL-17 axis, decreasing IL-17 levels (Noto Llana et al., 2013; Lenoir et al., 2016; Guo et al., 2023).”
Yamamoto, B., Suzuki, Y., Yonezu, T., Mizushima, N., Watanabe, N., Sato, T., Inoue, S., & Inokuchi, S. (2018) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2018.1443789 · Cited by 15
Soutto, M., Saleh, M. A., Arredouani, M. S., Piazuelo, B. M., Belkhiri, A., & El-Rifai, W. M. (2017) · Journal of Cancer · doi:10.7150/jca.19639 · Cited by 16
“CD4+T cells, which are key regulators of the immune system, differentiate into T helper (Th17) cell lineages that can promote chronic inflammation and tumor growth [52, 53].”
BackgroundBhukya, K. K., & Bhukya, B. (2022) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-10002-0 · Cited by 14
Probiotic immunonutrition impacts on colon cancer immunotherapy and prevention
Nami, Y., Hejazi, S., Geranmayeh, M. H., Shahgolzari, M., & Khosroushahi, A. Y. (2022) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000738 · Cited by 14
Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategies
Kang, Y., Pan, W. D., & Cai, Y. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-116387 · Cited by 13
“[62], mice were subcutaneously injected with DMH weekly during 10 weeks and orally administered with L.”
MethodThe impact of modulating the gastrointestinal microbiota in cancer patients
Morkūnas, E., Skiecevičienė, J., & Kupčinskas, J. (2020) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2020.101700 · Cited by 14
Zhao, Z., Yang, Q., Zhou, T., Liu, C., Sun, M., Cui, X., & Zhang, X. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04120-7 · Cited by 12
Bacteria-based cancer therapy: Looking forward
Tieu, M., Pham, D., & Cho, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189112 · Cited by 12
Fermented food products for gastrointestinal health and related diseases
Meena, S. K., Reddy, B. K., & Rai, D. C. (2023) · Journal of Dairy Veterinary & Animal Research · doi:10.15406/jdvar.2023.12.00320 · Cited by 12
RETRACTED ARTICLE: Anti-cancer activity of human gastrointestinal bacteria
Quazi, S. (2022) · Medical Oncology · doi:10.1007/s12032-022-01771-3 · Cited by 12
“However, the impact of lactobacilli on cancer cell viability or tumor size is mostly concentrated on the investigations [76, 140].”
RetractedUse of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?
Bermúdez‐Humarán, L. G., & Langella, P. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0016-2016 · Cited by 14
“Recent studies in preclinical murine models have also shown that Lactobacillus casei BL23 can stimulate systemic immunity and protect against intestinal inflammation (20) as well as colorectal cancer (15).”
ResultSelf-citationGut bacteria affect the tumoral immune milieu: distorting the efficacy of immunotherapy or not?
Pu, X., Chao, G., Dong, L., & Chang, P. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1739794 · Cited by 11
Metadata
- Authors
- Lenoir, M., del Carmen, S., Cortes-Perez, N. G., Lozano-Ojalvo, D., Muñoz-Provencio, D., Chain, F., Langella, P., de Moreno de LeBlanc, A., LeBlanc, J. G., & Bermúdez-Humarán, L. G.
- Affiliations
- AgroParisTech (FR)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Corresponding author
- LeBlanc, Jean Guy
- Venue
- Journal of Gastroenterology
- Published
- 2016-01-09
- Volume
- 51
- Issue
- 9
- Pages
- 862-873
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- OpenAlex
- W2227234059
- Cited by
- 155
- References
- 46
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 9 · 2023: 12 · 2022: 15 · 2021: 17 · 2020: 35 · 2019: 23 · 2018: 17 · 2017: 17 · 2016: 4
- FWCI
- 25.61
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2020-09-08)
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- CONICET Digital (CONICET) (submittedVersion, cc-by-nc-sa)
- Funders
- Ministerio de Educación, Cultura y Deporte
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, colorectal cancer, 1,2-dimethylhydrazine, regulatory T cells, Th17 cells, immunomodulation, intestinal inflammation, IL-22, IL-17, IL-10, TGF-beta, interleukin-6, retracted article
- MeSH terms
- Animals, Female, Lacticaseibacillus casei, Mice, Inbred BALB C, Mice, Inbred C57BL, Colorectal Neoplasms, Biomarkers, Cytokines, 1,2-Dimethylhydrazine, Probiotics, T-Lymphocytes, Regulatory, Mice, Th17 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.